Ocular Therapeutix, Inc.
OCUL
$9.16
-$0.12-1.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -38.34% | -33.62% | -90.22% | -54.91% | 1.23% |
| Total Depreciation and Amortization | 30.78% | 31.13% | 11.47% | 7.32% | 6.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.31% | 57.47% | 7,370.97% | -26.13% | -70.10% |
| Change in Net Operating Assets | -82.61% | -344.87% | 407.84% | -82.36% | 142.52% |
| Cash from Operations | -47.73% | -37.59% | -38.75% | -122.72% | -31.82% |
| Capital Expenditure | -141.18% | -1,305.45% | -6,633.71% | -67.79% | -658.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -141.18% | -1,305.45% | -6,633.71% | -50.27% | -658.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -92.97% | 9,857.37% | 147.87% | 4,353.83% | -98.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -92.97% | 9,857.37% | 147.87% | 4,353.83% | -98.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -65.86% | 1,217.06% | -42.78% | 277.54% | -114.78% |